Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.38M | -39.34M | -34.77M | -11.66M | 131.67M |
| Total Depreciation and Amortization | -867.00K | 467.00K | 872.00K | 808.00K | 536.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.94M | 8.87M | 9.00M | 11.52M | 6.33M |
| Change in Net Operating Assets | -2.67M | 28.06M | -3.88M | 124.69M | -167.72M |
| Cash from Operations | -36.98M | -1.94M | -28.78M | 125.36M | -29.18M |
| Capital Expenditure | -144.00K | -88.00K | -813.00K | -545.00K | -310.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.96M | -58.47M | 55.62M | -93.86M | -8.42M |
| Cash from Investing | 48.82M | -58.56M | 54.81M | -94.40M | -8.73M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.84M | 5.66M | 2.93M | 11.92M | 4.03M |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -479.00K | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.84M | 5.66M | 2.93M | 11.44M | 4.03M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 14.68M | -54.83M | 28.96M | 42.40M | -33.87M |